Heatwurx (PCSA) Expected to Announce Earnings on Thursday

Heatwurx (NASDAQ:PCSA) is expected to post its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect Heatwurx to post earnings of ($1.00) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 7:00 AM ET.

Heatwurx Stock Performance

NASDAQ:PCSA opened at $2.69 on Tuesday. The stock has a market cap of $7.40 million, a price-to-earnings ratio of -0.08 and a beta of 1.01. Heatwurx has a one year low of $1.76 and a one year high of $19.64. The business’s 50-day simple moving average is $2.75 and its 200 day simple moving average is $4.11.

Analyst Ratings Changes

A number of research analysts recently commented on PCSA shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Heatwurx in a report on Tuesday, April 21st. Wall Street Zen downgraded Heatwurx from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $25.00.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.